Literature DB >> 27424075

Risk stratification of ventricular fibrillation in Brugada syndrome using noninvasive scoring methods.

Hiroshi Kawazoe1, Yukiko Nakano2, Hidenori Ochi3, Masahiko Takagi4, Yusuke Hayashi4, Yuko Uchimura1, Takehito Tokuyama1, Yoshikazu Watanabe1, Hiroya Matsumura1, Shunsuke Tomomori1, Akinori Sairaku1, Kazuyoshi Suenari1, Akinori Awazu5, Yosuke Miwa6, Kyoko Soejima6, Kazuaki Chayama3, Yasuki Kihara1.   

Abstract

BACKGROUND: Risk stratification for ventricular fibrillation (VF) in patients with Brugada syndrome (BrS) remains controversial.
OBJECTIVE: The purpose of this study was to construct a novel prediction model for VF risk in BrS patients using noninvasive parameters.
METHODS: A total of 143 Japanese BrS patients with VF (n = 35) and without VF (n = 108) were retrospectively enrolled. We built a logistic regression model predicting VF occurrence and evaluated it by cross-validation.
RESULTS: Frequencies of history of syncope and spontaneous type 1 ECG, r-J interval in V1, QRS duration in V6, and LAS40, Tpeak-Tend dispersion, and max T-wave alternans were significantly associated with VF occurrence in univariate analyses. The history of syncope, r-J interval in V1, QRS duration in V6, and Tpeak-Tend dispersion were identified as independent predictors by multivariate logistic regression analysis. The predictive model was constructed using all these parameters with good discrimination of VF occurrence (area under the curve 0.869 with 97.1% sensitivity and 65.7% specificity). The area under the curve based on leave-one-out cross-validation was 0.845, with 97.1% sensitivity and 63.0% specificity suggesting good performance of the model. Retrospective survival analysis revealed that the cumulative VF event rate was significantly higher in patients at high risk than in those with low risk using the log rank test (P = 2.97 × 10(-8)). Notably, no BrS patient below the cutoff value developed a subsequent VF event.
CONCLUSION: This novel prediction method may effectively assesses VF risk in BrS patients, especially when determining implantable cardioverter-defibrillator placement for asymptomatic BrS patients.
Copyright © 2016 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brugada syndrome; Risk stratification; Scoring method; T-wave alternans; Ventricular fibrillation

Mesh:

Year:  2016        PMID: 27424075     DOI: 10.1016/j.hrthm.2016.07.009

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  18 in total

1.  Brugada syndrome trafficking-defective Nav1.5 channels can trap cardiac Kir2.1/2.2 channels.

Authors:  Marta Pérez-Hernández; Marcos Matamoros; Silvia Alfayate; Paloma Nieto-Marín; Raquel G Utrilla; David Tinaquero; Raquel de Andrés; Teresa Crespo; Daniela Ponce-Balbuena; B Cicero Willis; Eric N Jiménez-Vazquez; Guadalupe Guerrero-Serna; Andre M da Rocha; Katherine Campbell; Todd J Herron; F Javier Díez-Guerra; Juan Tamargo; José Jalife; Ricardo Caballero; Eva Delpón
Journal:  JCI Insight       Date:  2018-09-20

2.  The utility of T-wave alternans during the morning in the summer for the risk stratification of patients with Brugada syndrome.

Authors:  Shogo Sakamoto; Masahiko Takagi; Jun Kakihara; Yusuke Hayashi; Atsushi Doi; Kenichi Sugioka; Minoru Yoshiyama
Journal:  Heart Vessels       Date:  2016-08-01       Impact factor: 2.037

3.  Concomitant SK current activation and sodium current inhibition cause J wave syndrome.

Authors:  Mu Chen; Dong-Zhu Xu; Adonis Z Wu; Shuai Guo; Juyi Wan; Dechun Yin; Shien-Fong Lin; Zhenhui Chen; Michael Rubart-von der Lohe; Thomas H Everett; Zhilin Qu; James N Weiss; Peng-Sheng Chen
Journal:  JCI Insight       Date:  2018-11-15

Review 4.  Hypothetical "anatomy" of Brugada phenomenon: "Long QT sine Long QT" syndrome implicating morphologically undefined specific "Brugada's myocells".

Authors:  Petras Stirbys
Journal:  J Atr Fibrillation       Date:  2017-04-30

Review 5.  [Sudden cardiac death : Epidemiology, pathophysiology and risk stratification].

Authors:  B Rudic; E Tülümen; V Liebe; J Kuschyk; I Akin; M Borggrefe
Journal:  Herz       Date:  2017-04       Impact factor: 1.443

6.  Plasma MicroRNAs as noninvasive diagnostic biomarkers in patients with Brugada syndrome.

Authors:  Yoshihiro Ikeuchi; Hidenori Ochi; Chikaaki Motoda; Takehito Tokuyama; Yousaku Okubo; Sho Okamura; Syunsuke Miyauchi; Shogo Miyamoto; Yukimi Uotani; Yuko Onohara; Mika Nakashima; Rie Akiyama; Hidetoshi Tahara; Kazuaki Chayama; Yasuki Kihara; Yukiko Nakano
Journal:  PLoS One       Date:  2022-05-26       Impact factor: 3.752

7.  Restitution metrics in Brugada syndrome: a systematic review and meta-analysis.

Authors:  Gary Tse; Sharen Lee; Mengqi Gong; Panagiotis Mililis; Dimitrios Asvestas; George Bazoukis; Leonardo Roever; Kamalan Jeevaratnam; Sandeep S Hothi; Ka Hou Christien Li; Tong Liu; Konstantinos P Letsas
Journal:  J Interv Card Electrophysiol       Date:  2019-12-14       Impact factor: 1.900

Review 8.  Computational techniques for ECG analysis and interpretation in light of their contribution to medical advances.

Authors:  Aurore Lyon; Ana Mincholé; Juan Pablo Martínez; Pablo Laguna; Blanca Rodriguez
Journal:  J R Soc Interface       Date:  2018-01       Impact factor: 4.118

9.  Spontaneous type 1 pattern, ventricular arrhythmias and sudden cardiac death in Brugada Syndrome: an updated systematic review and meta-analysis.

Authors:  Ahmed Bayoumy; Meng-Qi Gong; Ka Hou Christien Li; Sunny Hei Wong; William Kk Wu; Guang-Ping Li; George Bazoukis; Konstantinos P Letsas; Wing Tak Wong; Yun-Long Xia; Tong Liu; Gary Tse
Journal:  J Geriatr Cardiol       Date:  2017-10       Impact factor: 3.327

10.  Long-term prognosis in patients with non-type 1 Brugada electrocardiogram: Results from a large Japanese cohort of idiopathic ventricular fibrillation.

Authors:  Tetsuji Shinohara; Masahiko Takagi; Tsukasa Kamakura; Yukio Sekiguchi; Yasuhiro Yokoyama; Naohiko Aihara; Masayasu Hiraoka; Kazutaka Aonuma
Journal:  Ann Noninvasive Electrocardiol       Date:  2021-02-19       Impact factor: 1.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.